Repare Therapeutics IncNASDAQ:RPTX
- LAST PRICE10.6300
- TODAY'S CHANGE (%)0.1200 (1.1418%)
- Bid / Lots10.5800/ 1
- Ask / Lots10.6500/ 2
- Open / Previous Close10.4700 / 10.5100
- Day Range
- 52 Week Range
- Volume52,633
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPTX |
|---|---|---|
| 09:32 ET | 383 | 10.47 |
| 09:39 ET | 100 | 10.57 |
| 09:48 ET | 300 | 10.42 |
| 09:52 ET | 100 | 10.42 |
| 09:54 ET | 100 | 10.28 |
| 09:57 ET | 200 | 10.29 |
| 10:01 ET | 100 | 10.62 |
| 10:10 ET | 100 | 10.59 |
| 10:14 ET | 100 | 10.39 |
| 10:15 ET | 2824 | 10.39 |
| 10:19 ET | 1850 | 10.33 |
| 10:21 ET | 200 | 10.32 |
| 10:26 ET | 1803 | 10.48 |
| 10:28 ET | 200 | 10.435 |
| 10:32 ET | 100 | 10.46 |
| 10:33 ET | 100 | 10.41 |
| 10:35 ET | 700 | 10.4 |
| 10:37 ET | 100 | 10.4 |
| 10:39 ET | 627 | 10.41 |
| 10:42 ET | 500 | 10.42 |
| 10:44 ET | 919 | 10.5 |
| 10:46 ET | 200 | 10.59 |
| 10:48 ET | 100 | 10.59 |
| 10:50 ET | 3373 | 10.5 |
| 10:55 ET | 300 | 10.47 |
| 10:57 ET | 100 | 10.46 |
| 11:02 ET | 100 | 10.59 |
| 11:06 ET | 300 | 10.6 |
| 11:15 ET | 400 | 10.51 |
| 11:18 ET | 100 | 10.59 |
| 11:22 ET | 100 | 10.505 |
| 11:24 ET | 100 | 10.585 |
| 11:33 ET | 800 | 10.5 |
| 11:47 ET | 1611 | 10.56 |
| 11:51 ET | 900 | 10.515 |
| 12:00 ET | 1599 | 10.46 |
| 12:03 ET | 100 | 10.62 |
| 12:07 ET | 100 | 10.62 |
| 12:16 ET | 400 | 10.53 |
| 12:18 ET | 379 | 10.5 |
| 12:23 ET | 348 | 10.5 |
| 12:25 ET | 100 | 10.61 |
| 12:39 ET | 100 | 10.61 |
| 12:41 ET | 118 | 10.51 |
| 12:48 ET | 100 | 10.62 |
| 12:52 ET | 100 | 10.62 |
| 12:54 ET | 200 | 10.61 |
| 12:59 ET | 100 | 10.5376 |
| 01:01 ET | 100 | 10.6 |
| 01:03 ET | 100 | 10.6 |
| 01:08 ET | 100 | 10.535 |
| 01:14 ET | 200 | 10.59 |
| 01:15 ET | 200 | 10.59 |
| 01:17 ET | 100 | 10.53 |
| 01:19 ET | 100 | 10.59 |
| 01:21 ET | 100 | 10.59 |
| 01:24 ET | 100 | 10.58 |
| 01:28 ET | 2100 | 10.5 |
| 01:30 ET | 100 | 10.5 |
| 01:33 ET | 100 | 10.56 |
| 01:35 ET | 500 | 10.51 |
| 01:37 ET | 200 | 10.54 |
| 01:39 ET | 100 | 10.605 |
| 01:42 ET | 200 | 10.56 |
| 01:44 ET | 300 | 10.62 |
| 01:46 ET | 300 | 10.62 |
| 01:51 ET | 100 | 10.66 |
| 01:55 ET | 100 | 10.64 |
| 01:57 ET | 100 | 10.53 |
| 02:00 ET | 100 | 10.6 |
| 02:02 ET | 100 | 10.57 |
| 02:04 ET | 400 | 10.585 |
| 02:06 ET | 100 | 10.695 |
| 02:09 ET | 100 | 10.635 |
| 02:18 ET | 1618 | 10.58 |
| 02:22 ET | 400 | 10.64 |
| 02:29 ET | 700 | 10.51 |
| 02:31 ET | 500 | 10.63 |
| 02:33 ET | 100 | 10.55 |
| 02:36 ET | 333 | 10.58 |
| 02:42 ET | 200 | 10.56 |
| 02:45 ET | 400 | 10.63 |
May 22, 2023
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 7:00AM ET on Monday May 22, 2023 by Business Wire
7:00AM ET on Monday May 22, 2023 by Business Wire
May 9, 2023
BRIEF-Repare Therapeutics Provides Business Update And Reports First Quarter 2023 Financial Results, from 5:40PM ET on Tuesday May 09, 2023 by Thomson Reuters
5:40PM ET on Tuesday May 09, 2023 by Thomson ReutersRepare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results, from 4:05PM ET on Tuesday May 09, 2023 by Business Wire
4:05PM ET on Tuesday May 09, 2023 by Business Wire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Repare Therapeutics Inc | 442.3M | -13.5x | --- |
Anika Therapeutics Inc | 399.3M | -17.7x | --- |
Alector Inc | 611.8M | -4.7x | --- |
Xeris Biopharma Holdings Inc | 352.9M | -4.5x | --- |
Fate Therapeutics Inc | 488.0M | -2.1x | --- |
Agenus Inc | 509.4M | -1.9x | --- |
Company Information
Repare Therapeutics Inc. is a clinical-stage precision oncology company engaged in developing synthetic lethality (SL) to the discovery and development of novel therapeutics. The Company uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. Using its SNIPRx platform, the Company is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. The Company’s product pipelines include Camonsertib ATR Inhibitor, RP-6306 PKMYT1 Inhibitor and RP-2119 Pol Inhibitor. Its RP-6306 is being developed as a highly potent and selective PKMYT1 inhibitor that preferentially kills tumor cells overexpressing CCNE1.
Contact Information
- Headquarters
- 7210 Frederick-Banting, Suite 100ST-LAURENT, QC, Canada H4S 2A1
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Thomas Civik
- President, Chief Executive Officer, Director
- Lloyd Segal
- Chief Financial Officer, Executive Vice President
- Steve Forte
- Executive Vice President, Chief Scientific Officer
- Michael Zinda
- Executive Vice President, Chief Medical Officer
- Maria Koehler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $442.3M |
|---|---|
Revenue (TTM) | $137.1M |
Shares Outstanding | 42.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.79 |
Book Value | $6.65 |
P/E Ratio | -13.5x |
Price/Sales (TTM) | 3.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -14.33% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
